​

Cogent Biosciences (COGT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

COGT Stock Forecast

Cogent Biosciences (COGT) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $14.00 and a low of $14.00. This represents a 220.37% increase from the last price of $4.37.

$4 $6 $8 $10 $12 $14 High: $14 Avg: $14 Low: $14 Last Closed Price: $4.37

COGT Stock Rating

Cogent Biosciences stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (70.00%), 3 Hold (30.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 3 7 Strong Sell Sell Hold Buy Strong Buy

COGT Price Target Upside V Benchmarks

TypeNameUpside
StockCogent Biosciences220.37%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$14.75
Last Closing Price$4.37$4.37$4.37
Upside/Downside--237.53%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25353--11
Mar, 25353--11
Feb, 25353--11
Jan, 25353--11
Dec, 24453--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 14, 2025Robert BurnsH.C. Wainwright$14.00$8.2569.70%220.37%
Sep 24, 2024David LebowitzCitigroup$15.00$10.6540.85%243.25%
Sep 03, 2024David LebowitzCitigroup$13.00$10.9518.72%197.48%
Sep 03, 2024Robert BurnsH.C. Wainwright$17.00$11.3749.52%289.02%
Mar 30, 2024Kelly ShiJefferies$20.00$6.72197.62%357.67%
Dec 14, 2022Needham$24.00$12.3294.81%449.20%
Jun 17, 2022Chris RaymondRaymond James$22.00$9.19139.39%403.43%
Jun 10, 2022Christopher LiuLeerink Partners$15.00$10.7439.66%243.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025ScotiabankOutperforminitialise
Jan 14, 2025H.C. WainwrightBuyBuyhold
Sep 24, 2024CitigroupBuyBuyhold
Sep 03, 2024CitigroupBuyBuyhold
Sep 03, 2024Piper SandlerOverweightOverweighthold
Sep 03, 2024H.C. WainwrightBuyBuyhold
May 24, 2024Piper SandlerOverweightOverweighthold
Dec 14, 2022NeedhamBuyinitialise
Dec 13, 2022GuggenheimBuyBuyhold
Jun 17, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.00$-2.42$-3.49----
Avg Forecast$-3.84$-2.32$-2.43$-2.31$-1.72$-0.66$0.71
High Forecast$-3.84$-1.89$-2.30$-1.82$-1.39$0.69$0.71
Low Forecast$-3.84$-2.48$-2.54$-2.74$-2.59$-1.77$0.71
Surprise %56.25%4.31%43.62%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.87M------
Avg Forecast$7.92M--$1.51M$70.04M$258.92M$490.88M
High Forecast$7.92M--$1.51M$70.04M$258.92M$490.88M
Low Forecast$7.92M--$1.51M$70.04M$258.92M$490.88M
Surprise %-0.65%------

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-66.45M$-192.41M$-255.86M----
Avg Forecast$-306.02M$-192.41M$-192.73M$-181.93M$-158.60M$-50.94M$56.56M
High Forecast$-306.02M$-150.89M$-183.13M$-145.21M$-111.02M$54.96M$56.56M
Low Forecast$-306.02M$-197.68M$-202.32M$-218.65M$-206.18M$-140.99M$56.56M
Surprise %-78.29%-32.76%----

COGT Forecast FAQ

Is Cogent Biosciences stock a buy?

Cogent Biosciences stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cogent Biosciences is a favorable investment for most analysts.

What is Cogent Biosciences's price target?

Cogent Biosciences's price target, set by 10 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $14 at the low end to $14 at the high end, suggesting a potential 220.37% change from the previous closing price of $4.37.

How does Cogent Biosciences stock forecast compare to its benchmarks?

Cogent Biosciences's stock forecast shows a 220.37% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Cogent Biosciences over the past three months?

  • April 2025: 27.27% Strong Buy, 45.45% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 27.27% Strong Buy, 45.45% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 27.27% Strong Buy, 45.45% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.

What is Cogent Biosciences’s EPS forecast?

Cogent Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.31, marking a -33.81% decrease from the reported $-3.49 in 2024. Estimates for the following years are $-1.72 in 2026, $-0.66 in 2027, and $0.71 in 2028.

What is Cogent Biosciences’s revenue forecast?

Cogent Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $1.51M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $70.04M, followed by $258.92M for 2027, and $490.88M for 2028.

What is Cogent Biosciences’s net income forecast?

Cogent Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-182M, representing a -28.89% decrease from the reported $-256M in 2024. Projections indicate $-159M in 2026, $-50.942M in 2027, and $56.56M in 2028.